Arvinas - ARVN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $68.75
Forecasted Upside: 142.42%
Number of Analysts: 18
Breakdown:
0 Sell Ratings
5 Hold Ratings
13 Buy Ratings
0 Strong Buy Ratings

^$28.36 As of 03/22/2023 04:24 PM ET

▼ -0.79 (-2.71%)

1 month | 3 months | 12 months

Get New Arvinas Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

^$68.75

▲ +142.42% Upside Potential

This price target is based on 18 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $68.75, with a high forecast of $95.00 and a low forecast of $27.00. The average price target represents a 142.42% upside from the last price of $28.36.

Current Consensus is Buy

The current consensus among 18 polled investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/28/2021

0 strong buy ratings
14 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/27/2021

0 strong buy ratings
15 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/27/2022

0 strong buy ratings
15 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/25/2022

0 strong buy ratings
12 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/23/2022

0 strong buy ratings
12 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/22/2022

0 strong buy ratings
13 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

2/20/2023

0 strong buy ratings
13 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/22/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/17/2023	Citigroup	Boost Target		$72.00 ➝ $77.00	Low
2/27/2023	Morgan Stanley	Lower Target	Equal Weight	$57.00 ➝ $36.00	Low
2/24/2023	HC Wainwright	Reiterated Rating	Buy	$90.00	Low
2/24/2023	Credit Suisse Group	Lower Target	Outperform	$81.00 ➝ $61.00	Low
1/31/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$90.00	Low
1/17/2023	Truist Financial	Lower Target	Buy	$100.00 ➝ $65.00	Low
1/12/2023	Guggenheim	Downgrade	Buy ➝ Neutral		Low
1/10/2023	Wedbush	Lower Target		$43.00 ➝ $27.00	Low
1/10/2023	Oppenheimer	Lower Target		$102.00 ➝ $95.00	Low
1/2/2023	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$83.00 ➝ $49.00	Low
12/5/2022	Citigroup	Lower Target	Buy	$88.00 ➝ $72.00	Low
11/28/2022	The Goldman Sachs Group	Reiterated Rating	Buy	$81.00	Low
11/23/2022	Truist Financial	Lower Target		$170.00 ➝ $100.00	Low
11/23/2022	Cantor Fitzgerald	Lower Target		$106.00 ➝ $90.00	Low
11/23/2022	Barclays	Lower Target	Overweight	$90.00 ➝ $70.00	Low
11/22/2022	Piper Sandler	Boost Target	Overweight	$76.00 ➝ $81.00	Low
11/22/2022	SVB Leerink	Lower Target	Outperform	$89.00 ➝ $74.00	Low
11/15/2022	Credit Suisse Group	Boost Target		$81.00	N/A
11/11/2022	Morgan Stanley	Lower Target	Equal Weight	$63.00 ➝ $57.00	Low
10/25/2022	Capital One Financial	Initiated Coverage	Overweight		Low
10/18/2022	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$80.00	Low
9/21/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		Low
9/9/2022	Barclays	Initiated Coverage	Overweight	$90.00	Low
8/18/2022	Citigroup	Lower Target		$103.00 ➝ $88.00	Low
8/8/2022	Oppenheimer	Lower Target	Outperform	$108.00 ➝ $102.00	Low
8/5/2022	Cantor Fitzgerald	Lower Target		$140.00 ➝ $115.00	Low
8/5/2022	SVB Leerink	Lower Target	Outperform	$91.00 ➝ $89.00	Low
8/5/2022	Credit Suisse Group	Lower Target	Outperform	$98.00 ➝ $78.00	Low
8/5/2022	HC Wainwright	Lower Target	Buy	$135.00 ➝ $90.00	Low
6/21/2022	Jefferies Financial Group	Initiated Coverage	Hold	$42.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$111.00 ➝ $89.00	Low
5/23/2022	Piper Sandler	Lower Target	Overweight	$116.00 ➝ $76.00	High
5/20/2022	Citigroup	Lower Target	Buy	$103.00	Low
5/9/2022	Wedbush	Downgrade	Outperform ➝ Neutral	$43.00	High
5/5/2022	Stifel Europe	Lower Target	Buy ➝ Buy	$85.00 ➝ $82.00	High
4/28/2022	Credit Suisse Group	Initiated Coverage	Outperform	$104.00	High
4/26/2022	Stifel Nicolaus	Lower Target		$93.00 ➝ $85.00	High
4/6/2022	Morgan Stanley	Initiated Coverage	Equal Weight	$65.00	Medium
4/1/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
3/1/2022	Stifel Nicolaus	Lower Target	Buy	$100.00 ➝ $93.00	Medium
3/1/2022	The Goldman Sachs Group	Lower Target	Buy	$157.00 ➝ $110.00	Medium
2/18/2022	Wedbush	Lower Target		$115.00 ➝ $98.00	Low
2/18/2022	SVB Leerink	Lower Target	Outperform	$97.00 ➝ $91.00	Low
2/10/2022	Wells Fargo & Company	Initiated Coverage	Overweight	$98.00	High
1/19/2022	The Goldman Sachs Group	Initiated Coverage	Buy	$157.00	Low
12/6/2021	Cowen	Initiated Coverage	Outperform		Low
11/4/2021	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High
10/14/2021	SVB Leerink	Initiated Coverage	Outperform	$115.00	High
9/29/2021	Stifel Nicolaus	Initiated Coverage	Buy	$115.00	Low
9/9/2021	Bank of America	Initiated Coverage	Buy	$110.00	High
8/9/2021	Roth Capital	Boost Target	Buy	$120.00 ➝ $135.00	Medium
8/5/2021	Piper Sandler	Boost Target	Overweight ➝ Overweight	$105.00 ➝ $125.00	High
7/23/2021	BMO Capital Markets	Boost Target	Outperform	$101.00 ➝ $111.00	High
7/23/2021	Citigroup	Boost Target	Buy	$118.00 ➝ $153.00	High
7/23/2021	HC Wainwright	Reiterated Rating	Buy	$100.00 ➝ $135.00	High
7/23/2021	Oppenheimer	Boost Target	Outperform	$100.00 ➝ $108.00	High
7/22/2021	Piper Sandler	Reiterated Rating	Overweight	$97.00 ➝ $105.00	High
7/22/2021	Truist Financial	Boost Target	Buy	$150.00 ➝ $170.00	High
5/20/2021	UBS Group	Initiated Coverage	Buy	$123.00	High
4/21/2021	Northern Trust Capital Markets	Initiated Coverage	Buy		Low
4/21/2021	Truist Financial	Initiated Coverage	Buy	$150.00	High
3/31/2021	BMO Capital Markets	Initiated Coverage	Outperform	$101.00	High
3/30/2021	Cantor Fitzgerald	Boost Target	Overweight	$121.00 ➝ $140.00	High
1/19/2021	Oppenheimer	Boost Target		$80.00 ➝ $100.00	Low
1/5/2021	Cantor Fitzgerald	Boost Target	Overweight	$66.00 ➝ $121.00	N/A
12/21/2020	Piper Sandler	Boost Target	Overweight	$58.00 ➝ $97.00	Low
12/15/2020	Smith Barney Citigroup	Boost Target		$43.00 ➝ $123.00	High
12/15/2020	Roth Capital	Boost Target	Buy	$65.00 ➝ $120.00	High
12/14/2020	HC Wainwright	Reiterated Rating	Buy	$60.00 ➝ $100.00	High
12/14/2020	BMO Capital Markets	Boost Target	Outperform	$62.00 ➝ $114.00	High
12/14/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High
12/14/2020	The Goldman Sachs Group	Boost Target	Buy	$78.00 ➝ $129.00	High
12/14/2020	Wedbush	Boost Target	Outperform	$62.00 ➝ $93.00	High
12/1/2020	Cantor Fitzgerald	Lower Target		$75.00 ➝ $66.00	Medium
10/9/2020	Cantor Fitzgerald	Reiterated Rating	Overweight		High
10/8/2020	Oppenheimer	Reiterated Rating	Hold		High
8/4/2020	Oppenheimer	Initiated Coverage	Hold		Low
6/1/2020	Citigroup	Upgrade	Neutral ➝ Buy	$45.00	Medium
5/31/2020	Oppenheimer	Initiated Coverage	Hold		Low
5/29/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
5/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Medium
5/11/2020	Oppenheimer	Initiated Coverage	Market Perform		Medium
5/4/2020	Roth Capital	Boost Target	Buy	$35.00 ➝ $65.00	High
4/29/2020	HC Wainwright	Reiterated Rating	Buy	$50.00 ➝ $60.00	Medium
4/14/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$75.00	Low
3/16/2020	Piper Sandler	Reiterated Rating	Buy	$58.00	High
1/30/2020	BMO Capital Markets	Reiterated Rating	Outperform	$62.00	High
1/24/2020	Wedbush	Boost Target	Outperform	$39.00 ➝ $60.00	Medium
1/6/2020	Piper Jaffray Companies	Boost Target	Overweight	$35.00 ➝ $58.00	N/A
12/20/2019	Cantor Fitzgerald	Boost Target	Overweight	$42.00 ➝ $75.00	Low
12/19/2019	HC Wainwright	Initiated Coverage	Buy	$50.00	High
11/25/2019	Guggenheim	Initiated Coverage	Buy	$50.00	High
11/14/2019	Roth Capital	Initiated Coverage	Buy	$35.00	Medium
11/13/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$32.00 ➝ $35.00	High
10/24/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$23.00 ➝ $38.00	Medium
9/24/2019	Wedbush	Initiated Coverage	Outperform	$35.00 ➝ $38.00	Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Outperform	$34.00	High
8/5/2019	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$42.00 ➝ $42.00	Medium
6/5/2019	Citigroup	Downgrade	Buy ➝ Neutral	$21.00 ➝ $22.00	High
5/8/2019	Piper Jaffray Companies	Boost Target	Overweight	$23.00 ➝ $32.00	High
4/11/2019	Evercore ISI	Initiated Coverage	Outperform		High
10/22/2018	Citigroup	Initiated Coverage	Buy ➝ Buy	$21.00	Low
10/22/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$17.00	High
10/22/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$23.00	High

(Data available from 3/22/2018 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

6 very positive mentions
11 positive mentions
1 negative mentions
2 very negative mentions

Mentions as of

8/24/2022

1 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/23/2022

3 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/23/2022

1 very positive mentions
7 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/22/2022

0 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/22/2022

5 very positive mentions
3 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

1/21/2023

4 very positive mentions
1 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/20/2023

6 very positive mentions
7 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

3/22/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

marketbeat.com
2/24/2023
Arvinas (NASDAQ:ARVN) Announces Earnings Results

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
3/21/2023
Arvinas (NASDAQ:ARVN) Given New $77.00 Price Target at Citigroup
marketbeat.com
3/17/2023
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Moderate Buy" by Analysts
americanbankingnews.com
3/17/2023
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 6.5% in February
marketbeat.com
3/8/2023
Tang Capital Management LLC Makes New Investment in Arvinas, Inc. (NASDAQ:ARVN)
marketbeat.com
2/24/2023
Arvinas (NASDAQ:ARVN) Rating Reiterated by HC Wainwright

Very Positive

marketbeat.com
3/10/2023
14,235 Shares in Arvinas, Inc. (NASDAQ:ARVN) Purchased by Engineers Gate Manager LP
marketbeat.com
3/3/2023
Tower Research Capital LLC TRC Purchases 3,377 Shares of Arvinas, Inc. (NASDAQ:ARVN)
marketbeat.com
3/2/2023
Eventide Asset Management LLC Invests $12.52 Million in Arvinas, Inc. (NASDAQ:ARVN)
marketbeat.com
2/27/2023
Research Analysts Issue Forecasts for Arvinas, Inc.'s Q1 2024 Earnings (NASDAQ:ARVN)
finance.yahoo.com
2/24/2023
A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Today's Range

Now: $28.36

$28.25

$29.66

50 Day Range

MA: $32.28

$27.03

$37.26

52 Week Range

Now: $28.36

$26.57

$75.39

Volume

205,501 shs

Average Volume

497,500 shs

Market Capitalization

$1.51 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?: The following Wall Street research analysts have issued reports on Arvinas in the last year: Barclays PLC, Cantor Fitzgerald, Capital One Financial Co., Citigroup Inc., Credit Suisse Group AG, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Stifel Europe, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ARVN.
What is the current price target for Arvinas?: 16 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $68.75, suggesting a possible upside of 135.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting ARVN will reach $95.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $27.00 for Arvinas in the next year.
View the latest price targets for ARVN.
What is the current consensus analyst rating for Arvinas?: Arvinas currently has 5 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARVN will outperform the market and that investors should add to their positions of Arvinas.
View the latest ratings for ARVN.
What other companies compete with Arvinas?: Other companies that are similar to Arvinas include Nuvalent, CureVac, Ironwood Pharmaceuticals, Syndax Pharmaceuticals and Pliant Therapeutics. Learn More about companies similar to Arvinas.
How do I contact Arvinas' investor relations team?: Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is (203) 535-1456 and its investor relations email address is [email protected] The official website for Arvinas is www.arvinas.com. Learn More about contacing Arvinas investor relations.

Arvinas - ARVN Stock Price Target and Predictions

Analyst Price Target for ARVN

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.74 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

What is the current price target for Arvinas?

What is the current consensus analyst rating for Arvinas?

What other companies compete with Arvinas?

How do I contact Arvinas' investor relations team?